**Core Concept**
The combination of erythromycin, a macrolide antibiotic, with certain drugs can lead to increased risk of ventricular arrhythmias due to the inhibition of the cytochrome P450 3A4 (CYP3A4) enzyme. This enzyme is responsible for metabolizing a wide range of drugs, including some that can cause arrhythmias.

**Why the Correct Answer is Right**
Erythromycin inhibits CYP3A4, which in turn leads to increased levels of drugs that are substrates for this enzyme. One such drug is quinidine, a Class IA anti-arrhythmic medication. Quinidine is metabolized by CYP3A4, and when erythromycin is co-administered, it can lead to increased quinidine levels, resulting in a higher risk of ventricular arrhythmias. This is an example of a pharmacokinetic interaction, where the combination of two drugs alters the metabolism or excretion of one or both drugs.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not provided.
* **Option B:** While other antibiotics may interact with CYP3A4, they are not commonly associated with the same risk of ventricular arrhythmias as quinidine.
* **Option C:** This option is not provided.
* **Option D:** This option is not provided.

**Clinical Pearl / High-Yield Fact**
Remember that macrolide antibiotics, including erythromycin, can interact with CYP3A4 substrates to increase the risk of ventricular arrhythmias. Be cautious when co-prescribing these antibiotics with Class IA anti-arrhythmic medications like quinidine.

**Correct Answer:** C.